Skip to main content
HR 3199 116th Congress House Commerce Congressional oversight Department of Commerce Evidence and witnesses Government studies and investigations Intellectual property Prescription drugs

Term Act of 2019

Introduced: June 11, 2019 Introduced by: Jeffries, Hakeem S. Democratic · New York See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 28, 2019
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Jun 11, 2019
Referred to the House Committee on the Judiciary.
Jun 11, 2019
Introduced in House
 Plain-English summary Congressional Research Service

Terminating the Extension of Rights Misappropriated Act of 2019 or the Term Act of 2019

This bill addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner shall have disclaimed patent protection from all the listed patents after the first patent expires.

This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs.

The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.

What's happening now June 28, 2019

Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

 Committees of jurisdiction 2